Mydecine Innovations Group Inc. (MYCOF)
OTC PINK OTC PINK Primary Summary
MYCOF Chart
Mydecine Innovations Group Inc. Dividends
Mydecine Innovations Group Inc. Earnings
| 14 Aug 2025 (In 2 weeks) Date | | - Cons. EPS | - EPS |
| 30 Jun 2025 Date | | - Cons. EPS | 0.03 EPS |
| 13 Nov 2024 Date | | - Cons. EPS | - EPS |
| 19 Aug 2024 Date | | - Cons. EPS | - EPS |
| 16 Aug 2024 Date | | - Cons. EPS | - EPS |
| 14 Aug 2025 (In 2 weeks) Date | | - Cons. EPS | - EPS |
| 30 Jun 2025 Date | | - Cons. EPS | 0.03 EPS |
| 13 Nov 2024 Date | | - Cons. EPS | - EPS |
| 19 Aug 2024 Date | | - Cons. EPS | - EPS |
| 16 Aug 2024 Date | | - Cons. EPS | - EPS |
Mydecine Innovations Group Inc. (MYCOF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Mydecine Innovations Group Inc. ever had a stock split?
Mydecine Innovations Group Inc. Profile
| Drug Manufacturers - Specialty & Generic Industry | Healthcare Sector | Mr. David Joshua Bartch CEO | OTC PINK Exchange | CA62849F2008 ISIN |
| CA Country | 3 Employees | - Last Dividend | 1 Apr 2019 Last Split | - IPO Date |
Overview
Mydecine Innovations Group Inc. is a pioneering biotechnology firm dedicated to crafting and commercializing psilocybin-based products aimed at transforming the treatment of mental health issues. With a strategic emphasis on combating nicotine addiction, the company stands at the forefront of developing innovative therapies for smoking cessation. Initially known as NewLeaf Brands Inc., the enterprise underwent a rebranding to Mydecine Innovations Group Inc. in June 2020, signaling a new direction focused on psychedelic medicine. Since its establishment in 2013, Mydecine has anchored its roots in Vancouver, Canada, positioning itself as a leader in the burgeoning field of psychedelic research and therapy.
Products and Services
- MYCO-001
A flagship product candidate, MYCO-001 is at the vanguard of Mydecine's portfolio, promising a revolutionary approach to treating various mental health conditions. This synthetic psilocybin compound is tailor-made for clinical settings, ensuring controlled and precise dosages for therapeutic use.
- MYCO-002
As another integral product under development, MYCO-002 is meticulously designed to address specific psychological ailments, encapsulating Mydecine's commitment to diversifying their therapeutic offerings in the realm of mental health treatment.
- MYCO-003
With a focus on innovation, MYCO-003 represents Mydecine’s endeavor to refine and enhance the efficacy of psilocybin-based treatments. This drug candidate is a testament to the company’s dedication towards evolving its product line to better serve the needs of those battling mental health issues.
- MYCO-004
MYCO-004 is part of Mydecine's comprehensive approach to developing a suite of psilocybin compounds, each tailored for unique therapeutic applications. The inclusion of MYCO-004 underscores the company's ambition to cover a wide spectrum of mental health conditions, employing the latest scientific advances in psychedelics.
In addition to its proprietary product lineup, Mydecine Innovations Group Inc. fosters a strategic partnership with Applied Pharmaceutical Innovation, enhancing their capacity for drug discovery, research, and development. This collaboration particularly focuses on empathogenic and entactogenic compounds, further bolstering Mydecine’s position in pharmaceutical innovation for mental health treatment.
Contact Information
